CN106659764B - 环状鞘脂激活蛋白原肽及其用途 - Google Patents

环状鞘脂激活蛋白原肽及其用途 Download PDF

Info

Publication number
CN106659764B
CN106659764B CN201580021626.3A CN201580021626A CN106659764B CN 106659764 B CN106659764 B CN 106659764B CN 201580021626 A CN201580021626 A CN 201580021626A CN 106659764 B CN106659764 B CN 106659764B
Authority
CN
China
Prior art keywords
peptide
cyclic
seq
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580021626.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659764A (zh
Inventor
伦道夫·S·瓦特尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to CN202111206782.0A priority Critical patent/CN113908253A/zh
Publication of CN106659764A publication Critical patent/CN106659764A/zh
Application granted granted Critical
Publication of CN106659764B publication Critical patent/CN106659764B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201580021626.3A 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途 Active CN106659764B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111206782.0A CN113908253A (zh) 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970853P 2014-03-26 2014-03-26
US61/970,853 2014-03-26
PCT/US2015/022745 WO2015148801A1 (en) 2014-03-26 2015-03-26 Cyclic prosaposin peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111206782.0A Division CN113908253A (zh) 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途

Publications (2)

Publication Number Publication Date
CN106659764A CN106659764A (zh) 2017-05-10
CN106659764B true CN106659764B (zh) 2021-11-02

Family

ID=54196396

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580021626.3A Active CN106659764B (zh) 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途
CN202111206782.0A Pending CN113908253A (zh) 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111206782.0A Pending CN113908253A (zh) 2014-03-26 2015-03-26 环状鞘脂激活蛋白原肽及其用途

Country Status (6)

Country Link
US (4) US10646541B2 (enExample)
EP (2) EP4154901A1 (enExample)
JP (4) JP6727129B2 (enExample)
CN (2) CN106659764B (enExample)
AU (4) AU2015235978B2 (enExample)
WO (1) WO2015148801A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3127549B1 (en) 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
CN106659764B (zh) * 2014-03-26 2021-11-02 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860226A1 (en) * 2011-12-22 2013-06-27 Randolph S. Watnick Saposin-a derived peptides and uses thereof
CN105358708A (zh) * 2013-03-14 2016-02-24 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
GB8518144D0 (en) 1985-07-18 1985-08-21 Univ Belfast Solid phase peptide synthesis
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4794150A (en) 1987-03-11 1988-12-27 Samuel Steel Synthesis of peptide analogs
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5180816A (en) 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5221754A (en) 1989-06-09 1993-06-22 Research Corporation Technologies, Inc. Reagents for rapid peptide synthesis
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
PT710243E (pt) 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5552471A (en) 1994-08-17 1996-09-03 The Perkin-Elmer Corporation Solid support reagents for the synthesis of 3'-Nitrogen containing polynucleotides
US6001966A (en) 1995-10-19 1999-12-14 Proligo Llc Method for solution phase synthesis of oligonucleotides and peptides
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
CA2304108A1 (en) 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US7094943B2 (en) 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6500431B1 (en) 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US6706252B1 (en) 1998-10-30 2004-03-16 Rx/Ibr Corporation Method of treating disease with radioisotopes conjugated to bioactive substances
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020168639A1 (en) 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
JP2004510751A (ja) 2000-10-05 2004-04-08 アレス　トレーディング　ソシエテ　アノニム 位置選択的液相ペグ化
WO2003102018A2 (en) 2002-06-03 2003-12-11 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040219609A1 (en) 2002-07-12 2004-11-04 Day Anthony G. Methods for modulating proteins not previously known as proteases
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
EP1605965B1 (en) 2003-03-26 2012-12-26 DeveloGen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
GB0318205D0 (en) 2003-08-02 2003-09-03 Albachem Ltd Synthetic method
WO2006119035A2 (en) 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. Vegf variants
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
CA2673229A1 (en) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Methods for the synthesis of cyclic peptides
EP3127549B1 (en) * 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
US8027291B2 (en) 2007-09-27 2011-09-27 Wireless Technology Solutions Llc Method and apparatus for transmitting transport channels over a physical channel of a cellular communication system
JP6063626B2 (ja) 2008-07-28 2017-01-18 チルドレンズ メディカル センター コーポレーション プロミニン−１ペプチド断片およびその使用
CA2822026C (en) 2009-12-17 2018-06-12 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
CN106659764B (zh) * 2014-03-26 2021-11-02 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860226A1 (en) * 2011-12-22 2013-06-27 Randolph S. Watnick Saposin-a derived peptides and uses thereof
CN105358708A (zh) * 2013-03-14 2016-02-24 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途

Also Published As

Publication number Publication date
AU2019204952A1 (en) 2019-07-25
EP4154901A1 (en) 2023-03-29
JP2023053978A (ja) 2023-04-13
CN113908253A (zh) 2022-01-11
JP7284726B2 (ja) 2023-05-31
US20200246419A1 (en) 2020-08-06
WO2015148801A1 (en) 2015-10-01
JP2017512799A (ja) 2017-05-25
AU2015235978B2 (en) 2019-08-08
JP2025010144A (ja) 2025-01-20
US20170173109A1 (en) 2017-06-22
AU2015235978A1 (en) 2016-10-20
EP3122369B1 (en) 2022-08-31
US11191805B2 (en) 2021-12-07
US10646541B2 (en) 2020-05-12
EP3122369A1 (en) 2017-02-01
CA2943802A1 (en) 2015-10-01
AU2021203082A1 (en) 2021-06-10
US20220152146A1 (en) 2022-05-19
US11654178B2 (en) 2023-05-23
JP2020117504A (ja) 2020-08-06
US20240139279A1 (en) 2024-05-02
AU2023204392A1 (en) 2023-08-03
EP3122369A4 (en) 2017-09-27
JP6727129B2 (ja) 2020-07-22
CN106659764A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
US20240139279A1 (en) Cyclic prosaposin peptides and uses thereof
KR20170033372A (ko) 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
CN111447941A (zh) 用于细胞内递送装订肽的多肽缀合物
JP2024517518A (ja) マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用
JP2023544223A (ja) 標的化ｐｅｔ／ｓｐｅｃｔ撮像のための放射性標識リガンド及びそれらの使用方法
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
HK40090948A (en) Cyclic prosaposin peptides and uses thereof
CA2943802C (en) Cyclic prosaposin peptides and uses thereof
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
US20150299258A1 (en) Peptide for Inhibiting Vascular Endothelial Growth Factor Receptor
EP2670416B1 (en) A novel high affinity bivalent helically constrained peptide against cancer
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof
HK1233930B (en) Cyclic prosaposin peptides and uses thereof
WO2024252336A1 (en) Peptide compositions targeting glypican-3 and uses thereof
KR20250028290A (ko) 선택적 il-23 수용체 길항제로서의 새로운 펩티드

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant